Managing dermatologic toxicities of epidermal growth factor receptor inhibitors.

Clinical lung cancer

Volumn 8 Suppl 1, Issue , 2006, Pages

  Chou, Lillian S ^a   Garey, Jody ^a   Oishi, Karen ^a   Kim, Edward ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; HER1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

CHEMICALLY INDUCED DISORDER; CLASSIFICATION; DRUG ANTAGONISM; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; PROTO ONCOGENE; RASH; REVIEW;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; EXANTHEMA; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

MLCS; MLOWN;

EID: 34249740340     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2006.s.009     Document Type: Article

References (33)